GetTopicDetailResponse(id=f5e81190998d, topicName=allo-HCT, introduction=, content=急性淋巴細胞白血病 ALL allo-HCT, image=null, comments=0, allHits=667, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Sep 14 17:08:01 CST 2024, time=2024-09-14, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=103779, tagList=[TagDto(tagId=103779, tagName=allo-HCT)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2276218, encodeId=290a22e621827, content=<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a> <a href='/topic/show?id=f5e81190998d' target=_blank style='color:#2F92EE;'>#allo-HCT#</a>, objectTitle=老年AML患者allo-HCT的供者：≥50歲MSD對比≤40歲HID, objectType=article, longId=890347, objectId=820289034eca, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739954931509_8538692.jpg, objectUrl=/article/show_article.do?id=820289034eca, replyNumber=0, likeNumber=12, createdTime=2025-08-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=820289034eca, moduleTitle=老年AML患者allo-HCT的供者：≥50歲MSD對比≤40歲HID, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=820289034eca)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2233615, encodeId=2f412233615f8, content=<a href='/topic/show?id=ca34223639f' target=_blank style='color:#2F92EE;'>#中等收入國家#</a> <a href='/topic/show?id=f5e81190998d' target=_blank style='color:#2F92EE;'>#allo-HCT#</a>, objectTitle=Front Immunol：門診allo-HCT+降低強度預(yù)處理方案治療ALL或AML的低收入中等收入國家患者的療效研究, objectType=article, longId=848877, objectId=32d98488e79f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721281386020_92910.jpg, objectUrl=/article/show_article.do?id=32d98488e79f, replyNumber=0, likeNumber=47, createdTime=2024-10-28, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=32d98488e79f, moduleTitle=Front Immunol：門診allo-HCT+降低強度預(yù)處理方案治療ALL或AML的低收入中等收入國家患者的療效研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=32d98488e79f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225866, encodeId=89322225866cf, content=<a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細胞白血病#</a> <a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a> <a href='/topic/show?id=f5e81190998d' target=_blank style='color:#2F92EE;'>#allo-HCT#</a>, objectTitle=【AJH】誘導(dǎo)方案強度和異基因移植對Ph陽性ALL患者生存的影響, objectType=article, longId=843114, objectId=2afa843114a0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230823/1692777212431_2570354.jpg, objectUrl=/article/show_article.do?id=2afa843114a0, replyNumber=0, likeNumber=110, createdTime=2024-09-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2afa843114a0, moduleTitle=【AJH】誘導(dǎo)方案強度和異基因移植對Ph陽性ALL患者生存的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2afa843114a0)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-09-14發(fā)表于上海
